journal
Journals Current Opinion in Endocrinolo...

Current Opinion in Endocrinology, Diabetes, and Obesity

https://read.qxmd.com/read/38966915/coronary-artery-event-free-or-resilient-familial-hypercholesterolemia-what-s-in-a-name
#1
JOURNAL ARTICLE
Seyed Saeed Tamehri Zadeh, Dick C Chan, Pedro Mata, Gerald F Watts
PURPOSE OF REVIEW: Familial hypercholesterolemia (FH) is an autosomal semi-dominant condition, characterized by excessive circulating low-density lipoprotein cholesterol (LDL-C) from birth that substantially accelerates the onset and progression of atherosclerotic cardiovascular disease (ASCVD), classically coronary artery disease (CAD). Elevated plasma LDL-C integrated over time is unequivocally the major determinant of ASCVD in heterozygous FH (HeFH); however, the wide variation in incidence and progression of ASCVD suggests a role for a wide spectrum of risk modifiers...
July 5, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38767063/hypoparathyroidism-update
#2
JOURNAL ARTICLE
Cherie Chiang
PURPOSE OF REVIEW: Since the release of the 2022 Second International Workshop Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines, updates and advances are now available in the cause, complications, and treatment of adult chronic hypoparathyroidism (hypoPTH). This review aims to highlight these new findings and implications to patient care. RECENT FINDINGS: Postsurgical hypoparathyroidism remains the most common cause, immune-related hypoparathyroidism from checkpoint inhibitors is an emerging autoimmune cause...
May 17, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38752851/the-use-of-anabolic-agents-in-the-treatment-of-osteoporosis-a-clinical-update
#3
JOURNAL ARTICLE
Charles A Inderjeeth, Diren C Inderjeeth
PURPOSE OF REVIEW: Anabolic therapies have revolutionized the management of patients with osteoporosis, especially those at very high fracture risk. The current review offers valuable insights into the latest evidence and guidelines on the use of anabolic agents, focusing on their comparative efficacy, safety profiles, and optimal implementation in clinical practice. RECENT FINDINGS: Romosozumab, abaloparatide, and teriparatide have shown superior efficacy when compared to antiresorptive therapies in increasing bone mineral density and reducing fracture risk...
May 17, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38716720/predictors-of-cardiovascular-risk-in-familial-hypercholesterolemia
#4
JOURNAL ARTICLE
Manuel Jesús Romero-Jiménez, María Elena Mansilla-Rodríguez
PURPOSE OF REVIEW: Familial Hypercholesterolemia is associated with an increased risk of cardiovascular disease. The current international guidelines of the main scientific societies consider that all people with familial hypercholesterolemia have a high or very high cardiovascular risk. However, the occurrence of atherosclerotic cardiovascular disease is very heterogeneous in this population. Stratifying risk within people with familial hypercholesterolemia is essential to identify individuals who require intensive cholesterol-lowering therapies...
May 9, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38687287/recent-advances-in-fibroblast-growth-factor-23-related-hypophosphatemic-disorders
#5
JOURNAL ARTICLE
Yuichi Takashi, Daiji Kawanami, Seiji Fukumoto
PURPOSE OF REVIEW: Fibroblast growth factor 23 (FGF23) is a hormone to reduce blood phosphate concentration. Excessive actions of FGF23 induce FGF23-related hypophosphatemic disorders, such as X-linked hypophosphatemic rickets (XLH) and tumor-induced osteomalacia (TIO). We will summarize recent advances in the diagnosis and treatment of FGF23-related hypophosphatemic disorders. RECENT FINDINGS: The measurement of blood FGF23 is useful to make a diagnosis of FGF23-related hypophosphatemic disorders...
May 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38916241/advances-in-assessment-and-treatment-of-bone-mineral-and-parathyroid-disorders
#6
EDITORIAL
Samuel D Vasikaran
No abstract text is available yet for this article.
August 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38916240/editorial-introduction
#7
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
August 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38809256/update-on-fracture-risk-assessment-in-osteoporosis
#8
REVIEW
Eugene McCloskey, Andre T H Tan, Marian Schini
PURPOSE OF REVIEW: The assessment of fracture risk is playing an ever-increasing role in osteoporosis clinical management and informing international guidelines for osteoporosis. FRAX, a fracture risk calculator that provides individualized 10-year probabilities of hip and major osteoporotic fracture, has been widely used since 2008. In this review, we recap the development and limitations of intervention thresholds and the role of absolute fracture risk. RECENT FINDINGS: There is an increasing awareness of disparities and inequities in the setting of intervention thresholds in osteoporosis...
August 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38804196/insight-into-the-potential-of-bone-turnover-biomarkers-integration-in-the-management-of-osteoporosis-and-chronic-kidney-disease-associated-osteoporosis
#9
REVIEW
Pauline Brouwers, Antoine Bouquegneau, Etienne Cavalier
PURPOSE OF REVIEW: Disturbances in mineral and bone metabolism occurring in osteoporosis and chronic kidney disease-associated osteoporosis place patients at high risk of fracture making these conditions a major public health concern. Due to the limited use of bone histomorphometry in clinical practice, the gold standard for assessing bone turnover, extensive efforts have been made to identify bone turnover markers (BTMs) as noninvasive surrogates. Since the identification of certain commonly used markers several decades ago, considerable experience has been acquired regarding their clinical utility in such bone disorders...
August 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38651507/editorial-overview
#10
JOURNAL ARTICLE
Horst Christian Weber
No abstract text is available yet for this article.
June 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38651506/editorial-introduction
#11
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
June 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38587099/the-interaction-between-gut-microbiome-and-bone-health
#12
REVIEW
Francesco Inchingolo, Angelo Michele Inchingolo, Fabio Piras, Laura Ferrante, Antonio Mancini, Andrea Palermo, Alessio Danilo Inchingolo, Gianna Dipalma
PURPOSE OF REVIEW: This review critically examines interconnected health domains like gut microbiome, bone health, interleukins, chronic periodontitis, and coronavirus disease 2019 (COVID-19), offering insights into fundamental mechanisms and clinical implications, contributing significantly to healthcare and biomedical research. RECENT FINDINGS: This review explores the relationship between gut microbiome and bone health, a growing area of study. It provides insights into skeletal integrity and potential therapeutic avenues...
June 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38533785/gut-motility-and-hormone-changes-after-bariatric-procedures
#13
REVIEW
Khushboo Gala, Wissam Ghusn, Barham K Abu Dayyeh
PURPOSE OF REVIEW: Metabolic and bariatric surgery (MBS) and endoscopic bariatric therapies (EBT) are being increasingly utilized for the management of obesity. They work through multiple mechanisms, including restriction, malabsorption, and changes in the gastrointestinal hormonal and motility. RECENT FINDINGS: Roux-en-Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy (LSG) cause decrease in leptin, increase in GLP-1 and PYY, and variable changes in ghrelin (generally thought to decrease)...
June 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38511400/gut-hormones-and-appetite-regulation
#14
REVIEW
So-Hyeon Hong, Kyung Mook Choi
PURPOSE OF REVIEW: Various gut hormones interact with the brain through delicate communication, thereby influencing appetite and subsequent changes in body weight. This review summarizes the effects of gut hormones on appetite, with a focus on recent research. RECENT FINDINGS: Ghrelin is known as an orexigenic hormone, whereas glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), cholecystokinin (CCK), postprandial peptide YY (PYY), and oxyntomodulin (OXM) are known as anorexigenic hormones...
June 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38483115/potassium-competitive-acid-blockers-and-acid-related-disorders
#15
JOURNAL ARTICLE
Kevin Z Huang, H Christian Weber
PURPOSE OF REVIEW: Potassium-competitive acid blockers (PCABs) represent a new class of compounds for the treatment of acid-related disorders. Recent FDA approval of the PCAB vonoprazan for erosive esophagitis has started an important new approach to acid-related disorders. RECENT FINDINGS: Compared to conventional proton pump inhibitors (PPIs), PCABs provide more rapid, potent, and sustained suppression of gastric acid with faster and more durable symptom relief...
June 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38411440/addressing-genetic-and-environmental-sources-of-cardiometabolic-disease
#16
JOURNAL ARTICLE
Gerald F Watts, Dick C Chan
No abstract text is available yet for this article.
April 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38411439/editorial-introduction
#17
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38334488/apoc3-sirna-and-aso-therapy-for-dyslipidemia
#18
REVIEW
Jasmine Chebli, Miriam Larouche, Daniel Gaudet
PURPOSE OF REVIEW: The aim of this review is to present the clinical indications of apolipoprotein C-III (apoC3) inhibition in the therapeutic arsenal for the treatment of lipid disorders and associated risks and to compare the most advanced modalities of apoC3 inhibition currently available or in development, specifically APOC3 antisense oligonucleotides (ASO) and small interfering RNA (siRNA). RECENT FINDINGS: ApoC3 inhibition significantly decreases triglyceride levels by mechanisms coupling both lipoprotein lipase (LPL) upregulation and LPL-independent mechanisms...
April 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38095480/bempedoic-acid-a-new-player-for-statin-intolerant-patients-and-beyond
#19
REVIEW
Salvatore Giordano, Carmen Anna Maria Spaccarotella, Giovanni Esposito, Ciro Indolfi
PURPOSE OF REVIEW: Low-density lipoproteins (LDL) cause atherosclerotic cardiovascular disease, a condition associated with significant morbidity and mortality. Statins represent the cornerstone for preventing cardiovascular events in patients with elevated LDL-cholesterol (LDL-C) levels, however, they are associated with frequent musculoskeletal adverse effects, which lead to drug discontinuation or limit their use to low (and less effective) doses. Bempedoic acid (BA) is a newly approved, safe, cholesterol-lowering agent that inhibits ATP-citrate lyase, an enzyme upstream to 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, the target of statins...
April 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/37994661/multifactorial-chylomicronemia-syndrome
#20
REVIEW
Alan Chait
PURPOSE OF REVIEW: The aim of this review was to understand the role of multifactorial chylomicronemia syndrome (MFCS) as a cause of severe hypertriglyceridemia; to distinguish it from other causes of severe hypertriglyceridemia; and to provide a rational approach to treatment. RECENT FINDINGS: There have been advances in understanding the genetic underpinning of MFCS, and a better appreciation as to how to differentiate it from the much rarer familial chylomicronemia syndrome, in which there are substantial differences in the approach to their treatment...
April 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
journal
journal
41662
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.